JP2007532666A5 - - Google Patents

Download PDF

Info

Publication number
JP2007532666A5
JP2007532666A5 JP2007508498A JP2007508498A JP2007532666A5 JP 2007532666 A5 JP2007532666 A5 JP 2007532666A5 JP 2007508498 A JP2007508498 A JP 2007508498A JP 2007508498 A JP2007508498 A JP 2007508498A JP 2007532666 A5 JP2007532666 A5 JP 2007532666A5
Authority
JP
Japan
Prior art keywords
seq
antiviral composition
group
nuclease
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007508498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007532666A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/012532 external-priority patent/WO2005115444A2/en
Publication of JP2007532666A publication Critical patent/JP2007532666A/ja
Publication of JP2007532666A5 publication Critical patent/JP2007532666A5/ja
Pending legal-status Critical Current

Links

JP2007508498A 2004-04-14 2005-04-14 ウイルス核酸を対象とした修飾ヌクレアーゼを用いた組成物及びウイルス性疾患の予防並びに治療方法 Pending JP2007532666A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56193404P 2004-04-14 2004-04-14
PCT/US2005/012532 WO2005115444A2 (en) 2004-04-14 2005-04-14 Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases

Publications (2)

Publication Number Publication Date
JP2007532666A JP2007532666A (ja) 2007-11-15
JP2007532666A5 true JP2007532666A5 (cg-RX-API-DMAC7.html) 2008-07-03

Family

ID=35451407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007508498A Pending JP2007532666A (ja) 2004-04-14 2005-04-14 ウイルス核酸を対象とした修飾ヌクレアーゼを用いた組成物及びウイルス性疾患の予防並びに治療方法

Country Status (7)

Country Link
US (2) US9592277B2 (cg-RX-API-DMAC7.html)
EP (1) EP1734991A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007532666A (cg-RX-API-DMAC7.html)
AU (2) AU2005247298B8 (cg-RX-API-DMAC7.html)
CA (1) CA2604243C (cg-RX-API-DMAC7.html)
IL (1) IL178802A0 (cg-RX-API-DMAC7.html)
WO (1) WO2005115444A2 (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US9248166B2 (en) 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
US8710012B2 (en) * 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
WO2006130034A1 (fr) * 2005-04-25 2006-12-07 Dmitry Dmitrievich Genkin Procede pour prolonger la duree de vie d'animaux ou de l'humain
EP1734991A4 (en) * 2004-04-14 2012-10-24 Avirid Inc COMPOSITIONS COMPRISING MODIFIED NUCLEASES DIRECTED AGAINST VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES
US20090011004A1 (en) * 2005-12-30 2009-01-08 Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
JP2009526045A (ja) * 2006-02-10 2009-07-16 デルマゲン アクティエボラーグ 新規抗菌ペプチド及びその使用
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases
CA2662520A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
EP2095825B8 (en) * 2006-11-28 2012-03-28 CLS Therapeutics Limited Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
WO2011031467A1 (en) * 2009-08-25 2011-03-17 Wayne State University Anti-cancer therapeutic strategy to overcome cancer resistance and to enable tailoring treatment to patients
GB0922066D0 (en) 2009-12-17 2010-02-03 Univ Belfast Modulator
EP2525835A4 (en) * 2010-01-18 2016-01-20 Univ Texas METHOD AND COMPOSITION FOR PARTICLE-CONTROLLED MEDICAMENTAL OUTPUT IN CANCER CELLS
KR101341640B1 (ko) * 2010-02-05 2013-12-16 한국전자통신연구원 단백질 미세 구조 분석 방법 및 단백질 미세 구조 분석용 어레이
US8981044B2 (en) * 2010-04-21 2015-03-17 National University Corporation Hokkaido University Lipid membrane structure having intranuclear migrating property
EP2490021A1 (en) * 2011-02-18 2012-08-22 Biotempt B.V. Modulators of PRR and GPCR signalling
WO2013126872A1 (en) * 2012-02-24 2013-08-29 Wayne State University Anti-cancer therapeutic strategy to overcome cancer resistance and to enable tailoring treatment to patients
JP2015527296A (ja) 2012-03-26 2015-09-17 アメリカ合衆国 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達
WO2014113493A1 (en) 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto
EP2969011A4 (en) * 2013-03-15 2017-03-01 Techulon Inc. Rapidly adaptable nano therapeutics for treatment of infectious disease
EP3035917A4 (en) * 2013-08-23 2017-03-01 Rutgers, the State University of New Jersey Biologically active synthetic nanoparticle constructs and methods of use therof
US11306326B2 (en) 2013-08-23 2022-04-19 Rutgers, The State University Of New Jersey Biologically active synthetic nanoparticle constructs and methods of use thereof
KR102467982B1 (ko) 2013-12-16 2022-11-16 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Vlp-레플리콘을 이용한 클래스 ii mhc 항원의 전달에 의한 암 면역요법
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
KR20170080579A (ko) 2014-10-01 2017-07-10 플랜트 헬스 케어, 인코포레이티드 파괴된 과민성 반응 박스를 갖는 유발제 펩티드 및 그의 용도
JP2017530197A (ja) 2014-10-01 2017-10-12 プラント ヘルス ケア インコーポレイテッド 過敏感反応エリシターペプチド及びその使用
RU2726131C2 (ru) 2015-05-22 2020-07-09 Дмитрий Дмитриевич Генкин Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
JP7341451B2 (ja) 2016-02-01 2023-09-11 エピアクシス セラピューティクス プロプライアタリー リミティド タンパク質性化合物とその利用
CN111587120A (zh) 2017-11-08 2020-08-25 艾比克斯治疗私人有限公司 免疫原性组合物及其用途
WO2019099685A1 (en) 2017-11-15 2019-05-23 Rutgers, The State University Of New Jersey Biodegradable hybrid inorganic nanoscaffolding materials and methods of use and manufacture thereof
CN111712468A (zh) 2017-12-22 2020-09-25 北卡罗莱纳州立大学 聚合物荧光团、包含其的组合物及制备和使用其的方法
EP3740581A4 (en) 2018-01-16 2021-10-27 CLS Therapeutics Limited TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WITH DESOXYRIBONUCLEASE (DNASE) ACTIVITY
JP7384906B2 (ja) * 2018-07-09 2023-11-21 ジーアールオー・バイオサイエンシズ・インコーポレイテッド 非標準アミノ酸含有組成物とその使用
WO2020106709A1 (en) * 2018-11-19 2020-05-28 Gro Biosciences Inc. Human dnase for lung disease
US11744925B2 (en) * 2019-01-28 2023-09-05 Microvention, Inc. Coatings
US12478684B2 (en) * 2019-04-11 2025-11-25 Northeastern University Oligonucleotide-polymer miktoarm conjugates and methods of use
WO2021046307A1 (en) * 2019-09-04 2021-03-11 North Carolina State University Hybridized poly(amidoamine)-amino acid dendrimers
US20250228954A1 (en) * 2020-01-24 2025-07-17 Sarepta Therapeutics, Inc. Designing Antisense Oligonucleotide Delivery Peptides by Interpretable Machine Learning
US20230346829A1 (en) * 2020-05-11 2023-11-02 Revir, Inc. Compositions and methods for treating viral infections
EP4149482A4 (en) * 2020-05-13 2024-05-22 Glycosyn LLC 2'-FUCOSYLLACTOSE FOR THE PREVENTION AND TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION
US11331329B2 (en) 2020-05-13 2022-05-17 Glycosyn LLC Fucosylated oligosaccharides for prevention of coronavirus infection
WO2022026689A1 (en) 2020-07-30 2022-02-03 Microvention, Inc. Antimicrobial coatings
US20220040315A1 (en) * 2020-08-09 2022-02-10 Fulu Labs Corporation Nuclease-dendrimer formulations for covid-19 and broad-spectrum antiviral therapy and prophylaxis
US20230263900A1 (en) * 2020-08-31 2023-08-24 Starpharma Pty Ltd. Dendrimer-drug conjugate
CN117651550A (zh) * 2021-07-02 2024-03-05 奥古尔·米尔扎尤索夫娜·穆萨哈诺娃 用于预防SARS-CoV-2感染的药物
CN114250208B (zh) * 2021-12-22 2023-07-25 武汉瀚海新酶生物科技有限公司 耐高盐高活性DNase I突变体的制备及应用
WO2024092230A2 (en) * 2022-10-28 2024-05-02 The Regents Of The University Of California Recombinant enhanced antiviral restrictors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5115096A (en) 1988-04-15 1992-05-19 Oncogen Amphiregulin: a bifunctional growth modulating glycoprotein
EP0460021A4 (en) * 1989-02-23 1992-08-26 Seragen, Inc. Chimeric toxin
US5629173A (en) * 1990-08-09 1997-05-13 Genentech, Inc. Methods of use of serine protease variants having peptide ligase activity
US5989886A (en) * 1991-01-02 1999-11-23 The Johns Hopkins University Method for the inhibition and prevention of viral replication using fusions of a virus protein and a destructive enzyme
US5792640A (en) * 1992-04-03 1998-08-11 The Johns Hopkins University General method to clone hybrid restriction endonucleases using lig gene
US5484589A (en) 1992-04-20 1996-01-16 Rufeld, Inc. Anti-viral methods using RNAse and DNAse
US5503973A (en) 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
WO1995000170A1 (en) 1993-06-24 1995-01-05 Rufeld, Inc. Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i
RU2066551C1 (ru) 1994-03-23 1996-09-20 Институт нефтехимического синтеза РАН Способ получения инсулинсодержащих полимерных гидрогелей
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5997861A (en) * 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US7432048B2 (en) * 1996-11-29 2008-10-07 Third Wave Technologies, Inc. Reactions on a solid surface
US5739512A (en) 1996-05-30 1998-04-14 Sun Microsystems, Inc. Digital delivery of receipts
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6280991B1 (en) 1997-10-15 2001-08-28 Wisconsin Alumni Research Foundation Engineered cytotoxic ribonclease
US6017537A (en) * 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
WO2000037658A2 (en) 1998-12-21 2000-06-29 Genencor International, Inc. Chemically modified enzymes with multiple charged variants
US6485718B1 (en) 1999-04-13 2002-11-26 Pharmacia Corporation Site specific ligation of proteins to synthetic particles
HUP0201425A3 (en) * 1999-04-23 2006-07-28 Hadasit Med Res Service Conjugate having a cleavable linkage for use in a liposome
WO2001013957A2 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US20010053521A1 (en) * 1999-09-27 2001-12-20 Kreimer David I. Amplification of analyte detection by substrates having particle structures with receptors
US6312956B1 (en) 1999-10-01 2001-11-06 Vanderbilt University Nuclear targeted peptide nucleic acid oligomer
US6962906B2 (en) 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US7091026B2 (en) 2001-02-16 2006-08-15 University Of Iowa Research Foundation Artificial endonuclease
US20030125241A1 (en) 2001-05-18 2003-07-03 Margit Wissenbach Therapeutic uses of LNA-modified oligonucleotides in infectious diseases
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
GB0126251D0 (en) * 2001-11-01 2002-01-02 Imp College Innovations Ltd Methods
EA008940B1 (ru) 2002-09-13 2007-10-26 Репликор, Инк. Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
JP2008505853A (ja) * 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
EP1734991A4 (en) * 2004-04-14 2012-10-24 Avirid Inc COMPOSITIONS COMPRISING MODIFIED NUCLEASES DIRECTED AGAINST VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES

Similar Documents

Publication Publication Date Title
CA2604243A1 (en) Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
Fuchs et al. Pathway for polyarginine entry into mammalian cells
KR102641844B1 (ko) 핵산 및 단백질 페이로드 전달을 위한 방법 및 조성물
TWI616531B (zh) 穿膜胜肽以及包含該胜肽之共軛物及組成物（二）
TWI655204B (zh) 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
Bolhassani Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer
EP2928907B1 (en) Cell penetrating peptides for intracellular delivery of molecules
EP2928906B1 (en) Cell penetrating peptides for intracellular delivery of molecules
TWI598441B (zh) 穿膜胜肽以及包含該胜肽之共軛物及組成物（四）
JP5670875B2 (ja) カーゴ分子の送達ビヒクルおよび炎症反応を免疫調節するための生物学的治療剤としてのＹｏｐＭ
Wolf et al. Structural requirements for cellular uptake and antisense activity of peptide nucleic acids conjugated with various peptides
JP2014524738A5 (cg-RX-API-DMAC7.html)
CA2805403A1 (en) Bioengineered silk protein-based nucleic acid delivery systems
JP2010508022A5 (cg-RX-API-DMAC7.html)
Naik et al. Different roles of cell surface and exogenous glycosaminoglycans in controlling gene delivery by arginine-rich peptides with varied distribution of arginines
Francoia et al. Everything You Always Wanted to Know about Poly‐l‐lysine Dendrigrafts (But Were Afraid to Ask)
KR20210038841A (ko) 게놈 편집을 위한 방법 및 조성물
CN106795205A (zh) 新细胞膜穿透肽及其作为生物活性物质传递体的用途
CA2390104C (en) Method for transfer of molecular substances with prokaryotic nucleic acid-binding proteins
Oehlke et al. Studies on the cellular uptake of substance P and lysine‐rich, KLA‐derived model peptides
US20040072743A1 (en) Pharmaceutical composition of modified pna molecules
Futami et al. Design of cytotoxic ribonucleases by cationization to enhance intracellular protein delivery
Langedijk et al. New transport peptides broaden the horizon of applications for peptidic pharmaceuticals
WO2001027261A2 (en) Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino
US8722617B2 (en) Mussel adhesive protein derived vectors for gene delivery